Technology
Health
Biotechnology

Capricor

$0.329
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.05 (-13.51%) Today
+$0.009 (2.81%) After Hours

Why Robinhood?

You can buy or sell Capricor and other stocks, options, ETFs, and crypto commission-free!

About

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. Read More The company was founded in August 2005 and is headquartered in Beverly Hills, CA.

Employees
22
Headquarters
Beverly Hills, California
Founded
2005
Market Cap
10.77M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
221.24K
High Today
$0.3785
Low Today
$0.311
Open Price
$0.37
Volume
357.00K
52 Week High
$1.58
52 Week Low
$0.31

Collections

Technology
Health
Biotechnology
Therapy
Medical
US
North America
Female CEOs

News

Seeking AlphaMay 13

Capricor Therapeutics, Inc. CEO Linda Marbán on Q1 2019 Results - Earnings Call Transcript

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2019 Earnings Conference Call May 13, 2019 4:30 PM ET Company Participants AJ Bergmann - CFO Linda Marbán - President and CEO Conference Call Participants Joe Pantginis - H.C. Wainwright Jason McCarthy - Maxim Group Operator Welcome to Capricor Therapeutics First Quarter 2019 Conference Call. My name is Chris and I'll be your operator for today's call. [Operator Instructions] As a reminder this call will be recorded. I would now like to turn the call ove...

113
Yahoo FinanceMay 13

Capricor Therapeutics Reports Q1 Loss, Lags Revenue Estimates

Capricor (CAPR) delivered earnings and revenue surprises of 27.27% and -42.25%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

47
Seeking AlphaMay 13

Data readout from mid-stage study of Capricor's CAP-1002 expected next quarter; shares up 5% after hours

Capricor Therapeutics (NASDAQ:CAPR) Q1 highlights: Net loss: ($2.5M); loss/share: ($0.08). Quick assets totaled $7.2M at quarter-end. Key future event: Analysis of interim data from Phase 2 HOPE-2 study evaluating CAP-1002 in DMD in early Q3. Enrollment of new patients contingent on additional funding (and other factors)....

34

Earnings

-$0.19
-$0.15
-$0.12
-$0.08
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
-$0.08 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.